Compare BCAL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | ABUS |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.1M | 836.0M |
| IPO Year | 2020 | 2008 |
| Metric | BCAL | ABUS |
|---|---|---|
| Price | $21.86 | $4.35 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $24.75 | N/A |
| AVG Volume (30 Days) | 187.5K | ★ 6.3M |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 777.27 | 55.26 |
| EPS | ★ 0.86 | 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $1.36 | $1,208.75 |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | $25.20 | ★ $4.98 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $16.61 | $3.50 |
| 52 Week High | $22.41 | $5.45 |
| Indicator | BCAL | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 35.56 |
| Support Level | $20.52 | $4.17 |
| Resistance Level | $21.87 | $4.57 |
| Average True Range (ATR) | 0.40 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 68.57 | 15.43 |
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.